Jiwei New Energy Hit Daily Limit in 1 Minute with "20cm" Rise! Vitamins Enter Price Increase Channel, Beneficiary Stocks Scarce (List Attached)

Institutions are optimistic about the performance of vitamin prices.

300317, 1-minute “20cm” limit-up

On the morning of March 18, Jawi New Energy (300317) opened sharply higher, and within about one minute after the bidding, it hit the “20cm” limit-up. By the close of trading that morning, the stock was at 6.03 yuan per share, up nearly 15%.

According to the company’s 2025 semi-annual report, Jawi New Energy’s main businesses include new energy power generation and the research, production, and sales of photovoltaic consumer products. Specifically, the new energy power generation segment can be divided into EPC and operation & maintenance of photovoltaic power stations, investment and operation of photovoltaic stations, and related industrial and commercial energy storage; photovoltaic consumer products involve the integrated application of solar cell technology and LED light sources, primarily generating electricity through solar photovoltaic power and applying it to LED lighting. This has led to various lighting applications, including solar lawn lights, garden lights, and low-voltage lamps.

The strong momentum of the green power concept may be a key reason for the stock’s unusual movement today. This morning, several other stocks such as Yabo Co., Ltd., Jicheng Electronics, and Meili Cloud also hit the daily limit.

Vitamin prices enter an upward channel

Recently, prices of vitamins A, E, and other products have surged significantly. According to Pacific Securities research, citing Baichuan Yingfu data, since the outbreak of Middle Eastern conflicts at the end of February, vitamin A prices have risen from 59 yuan/kg to 80 yuan/kg, a 35% increase, and vitamin E prices from 57 yuan/kg to 79 yuan/kg, a 38% increase. The firm pointed out that Europe has large production capacity for vitamins A and E, and future tight oil and gas supplies could significantly impact production, benefiting leading domestic companies.

China Post Securities also stated that the prices of vitamin raw materials were at historically low levels before the recent increases. Rising upstream chemical raw material costs and higher shipping prices have stimulated industry-wide production cuts and price hikes. Since vitamins are mainly used as feed additives with a very low cost proportion, downstream buyers are less sensitive to price increases, making price hikes easier and with more room for growth. China Post Securities believes that, driven by multiple factors, vitamins are just beginning to enter a price increase channel, and historical experience suggests significant potential for future gains.

Scarcity of beneficiary stocks

China Post Securities recommends paying attention to four related stocks.

Yifan Pharmaceutical: A leading company in calcium pantothenate, with cost advantages. Rising calcium pantothenate prices will expand profit margins. The company’s innovation and diversification are steadily progressing, which could support fundamentals during a cycle recovery.

Zhejiang Medicine: Has production capacity for VA, VE, VD3, and other varieties. Vitamin business accounts for a high proportion of revenue, and rising prices will amplify the company’s profit elasticity.

Nentech Technology: An important producer of VE. Its subsidiary, Nentech Technology (Shishou) Co., Ltd., and the joint venture Yimante Health Industry (Jingzhou) Co., Ltd., operate VE businesses. The rebound in VE prices will benefit the company.

Brothers Technology: An integrated layout of VB1, VB3, calcium pantothenate, and vitamin K3. Benefiting from the prosperity of B1 and the synergistic rise of B3, along with cost reduction, efficiency improvements, and product upgrades, the company’s profits are expected to continue recovering. The rise in calcium pantothenate prices will further boost performance.

Related concept stocks in A-shares are scarce. Wind data shows there are 14 vitamin concept stocks in total. Among them, Xinhecheng has a market value exceeding 100 billion yuan and is the only company in the sector with a market cap over 100 billion. Huatai Securities states that in the medium to long term, Xinhecheng’s capacity for methionine and vitamins, due to its significant advantages in energy, labor, and manufacturing costs compared to overseas companies, is expected to continue increasing its global market share amid declining overseas supply stability and potential exits.

Over the past year, stocks such as Xinhecheng, Weixin Kang, Minsheng Health, and Jindawi have received high institutional attention. Xinhecheng recently indicated that vitamin prices have stabilized and rebounded since Q4 last year. Additionally, companies like Brothers Technology have also mentioned price increases in related products in their earnings forecasts. Brothers Technology expects its 2025 performance to grow year-over-year, mainly due to higher prices for some vitamins, increased production and sales of benzophenone, and reduced costs for certain products, leading to overall improved profitability compared to the previous year.

(Source: Data Treasure)